Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000571413 | SCV000673240 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-02-18 | criteria provided, single submitter | clinical testing | The p.T18M variant (also known as c.53C>T), located in coding exon 1 of the CDKN2A gene, results from a C to T substitution at nucleotide position 53. The threonine at codon 18 is replaced by methionine, an amino acid with similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV000793102 | SCV000932442 | uncertain significance | Familial melanoma | 2023-01-24 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 485513). This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 18 of the CDKN2A (p16INK4a) protein (p.Thr18Met). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with CDKN2A (p16INK4a)-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Color Diagnostics, |
RCV000571413 | SCV001340205 | uncertain significance | Hereditary cancer-predisposing syndrome | 2018-12-11 | criteria provided, single submitter | clinical testing |